Financial analysts on Wall Street have revised their ratings and price targets for several U.S.-listed companies, including Factset, Lensar, and Starbucks, on Wednesday.
Key highlights: – Factset (FDS.N): RBC lowers price target from $320 to $243 – Lensar Inc (LNSR.O): BTIG raises price target from neutral to buy – Sable Offshore Corp (SOC.N): Gerdes Energy Research shifts from buy to neutral – Starbucks (SBUX.O): RBC downgrades from outperform to perform in the sector – Weatherford International Plc (WFRD.O): RBC initiates coverage with an outperform rating
The following is a summary of research actions on American companies reported by Reuters on Wednesday, listed alphabetically:
– Alto Neuroscience Inc (ANRO.N): Baird raises price target from $22 to $41 – Brightspring Health Services Inc (BTSG.O): TD Cowen increases price target from $49 to $60 – Docusign Inc (DOCU.O): JP Morgan lowers price target from $78 to $65 – Factset (FDS.N): RBC reduces target price to $243 from $320 – Healthequity Inc (HQY.O): RBC reduces target price from $110 to $100 – Highpeak Energy Inc (HPK.O): Gerdes Energy Research shifts from neutral to sell – IBM (IBM.N): JP Morgan reduces target price from $317 to $283 – Lennar Corp (LEN.N): KBW reduces price target to $105 from $115 – Lensar Inc (LNSR.O): BTIG raises from neutral to buy – Navient Corp (NAVI.O): Jefferies lowers price target to $9 from $13 – Oklo Inc (OKLO.N): Canaccord Genuity reduces price target from $175 to $125 – Sable Offshore Corp (SOC.N): Gerdes Energy Research shifts from buy to neutral – Starbucks (SBUX.O): RBC downgrades from outperform to perform in the sector – Topbuild Corp (BLD.N): D.A. Davidson reduces price target from $485 to $465 – Weatherford International Plc (WFRD.O): RBC initiates coverage with an outperform rating and a price target of $105
